The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results presented from the Phase I/II LIMBER-104 trial (NCT04455841), investigating the ALK2 inhibitor zilurgisertib as a monotherapy and in combination with ruxolitinib for patients with anemia due to myelofibrosis (MF). Dose escalation is ongoing and anemia responses have been observed in both the monotherapy and combination settings in non-transfusion-dependent patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
